CorMedix Inc. (CRMD) has been granted further extension time until June 30, 2013 to regain compliance with certain continued listing standards of the NYSE-MKT. The company was informed by the NYSE MKT on April 20, 2012 of not being in compliance due to financial impairment.
CRMD closed Monday's trading at $0.78, down 0.64%.
Based on a review of its quarterly report on Form 10-Q for the period ended December 31, 2012, iBio Inc. (IBIO) has been informed by NYSE MKT that it is currently not in compliance with an additional continued listing standard.
The criterion applies if a listed company has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether the company will be able to continue operations and/or meet its obligations as they mature.The company has been afforded the opportunity to submit an updated plan of compliance to the Exchange by May 6, 2013.
IBIO lost 4.55% on Monday to close at $0.48. In extended trading, the stock shed another 2.19% to $0.47.
Merck & Co. Inc. (MRK) has entered into a non-exclusive agreement with Bristol-Myers Squibb (BMY) to conduct a phase II trial of a once-daily oral combination regimen consisting of Bristol-Myers's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.
MRK closed Monday's trading at $47.92, up 0.91%.
Shares of NanoViricides Inc. (NNVC.OB) gained more than 8% on Monday after the company said it anticipates its oral and injectable FluCide drug candidates to be effective against the novel H7N9 strain that has caused human fatalities in China in recent months. A pre-IND meeting with the FDA was held last March for the injectable FluCide drug candidate, and the company has been working on the IND enabling studies.
Neuralstem Inc. (CUR) has been given the go-ahead by the FDA to begin dosing the third and final cohort of patients in its ongoing phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder. The phase Ib study, which is evaluating the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients in three cohorts, is expected to conclude in the third quarter of 2013.
CUR closed Monday's trading at $1.14, up 2.70%.
Plandai Biotechnology Inc. (PLPL) has entered into a license agreement with Phyto Nutricare PLC, a UK company, to develop and market Phytofare extracts for nutraceutical applications.
Under the terms of the agreement, Phyto Nutricare will pay Plandai a one-time license fee of $2 million, and then a recurring payment equal to 5% of future profits from Phytofare product sales. Sales of Phytofare are expected to commence in Q4 of 2013.
3SBio Inc. (SSRX) announced Monday that it has received a revised "going private" offer at $16.70 per ADS from Jing Lou, the company's Chairman and CEO, and CPEChina Fund, L.P. The company noted that its independent committee of its board of directors will consider the revised offer with its legal and financial advisors. The CEO had tabled a going private proposal at $15 per ADS last September.
SSRX closed Monday's trading 7.11% higher at $16.27.
Titan Pharmaceuticals Inc. (TTNP.OB) will make presentations of its investigational subdermal implant, Probuphine, for the maintenance treatment of adult patients with opioid dependence, at two upcoming medical meetings - on April 26 and on May 20, 2013.
The FDA is expected to announce its decision on Probuphine on April 30, 2013.
The Probuphine NDA, which was reviewed by an FDA panel, won the backing of the members last month - with 10-5 votes in favor of the effectiveness, and 12-2 votes in favor of safety of Probuphine.
The FDA usually follows the recommendations of its panels although it is not mandatory.
Titan Pharma has a license deal in place with Braeburn Pharmaceuticals for the commercialization of Probuphine in the United States and Canada that was signed last December.
ViroPharma Inc. (VPHM) announced that its experimental non-antibiotic - VP20621, demonstrated high rates of colonization and statistically significant reductions in recurrence of C. difficile infection in a phase II study.
VP20621 contains spores of a naturally occurring non-toxin producing strain of C. difficile.
Clostridium difficile is a bacteria present in everyone's intestine but in small numbers, and is kept 'under control' by the beneficial bacteria in our digestive tracts. But when we are taking antibiotics, many of the beneficial bacteria in our intestines are killed, paving way for Clostridium difficile to multiply in high numbers, causing infection.
The phase II study enrolled 168 adults previously treated for C. difficile infection with oral vancomycin or metronidazole, and they were randomized to receive either placebo or VP20621 for 14 days.
According to the study results, VP20621 was well tolerated and it significantly reduced the incidence of CDI recurrence.
VPHM closed Monday's trading at $26.32, up 1.19%.
Warner Chilcott plc (WCRX) on Monday received FDA approval for its new oral contraceptive - MINASTRINTM 24 FE. The drug is manufactured for Warner Chilcott by a third party. It is likely that MINASTRIN 24 FE may not hit drug stores shelves during 2013.
WCRX closed Monday's trading at $13.76, down 0.86%. In after-hours, the stock was up 0.55% at $13.84.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.